sent_id	id1	id2	out1	out2	label
91	1845	754	the effect on markers of bone turnover at 24 weeks	the level of serum procollagen type I N-terminal propeptide (PINP), a marker of bone formation,	0
624	937	815	severity of IAD	recovered completely from IAD	1
507	1577	819	the average FEV 1 from the first intake of study drug to the measurement at 90 minutes	relief of acute bronchoconstriction	0
344	941	306	the Gastrointestinal Symptom Rating Scale-IBS version (GSRS-IBS) 42	avoidance behaviors	0
738	1896	637	The plaque scores	plaque index	1
683	1816	851	disability	disability	1
753	1936	55	changes compared to baseline observed after 4 weeks (40 sessions) of treatment, in parallel groups, on (1) Aberrant Behavior Checklist–Community (ABC) total score and subscale scores, based on the parent's or primary caretaker's rating, (2) Autism Treatment Evaluation Checklist (ATEC) total score and subscale scores, based on the parent's or primary caretaker's rating, and (3) Clinical Global Impression–Improvement (CGI) scale for changes in overall functioning and subscales, as rated by the parent or primary caretaker and also as rated separately by the treating physician (without knowledge of the parental ratings)	receptive language	0
365	625	388	self-reported withdrawal symptom severity during the detoxification period	relapse rate	0
400	1481	41	Depressive symptoms	The percentages of participants with severe depressive symptoms	1
239	406	263	a dichotomous measure (occurrence of low back pain)	The overall response rate	0
311	513	200	Early Treatment Failure (ETF); Late Clinical Failure (LCF); Late Parasitological Failure (LPF); Adequate Clinical and Parasitological Response (ACPR) 18	effectiveness	0
758	1936	60	changes compared to baseline observed after 4 weeks (40 sessions) of treatment, in parallel groups, on (1) Aberrant Behavior Checklist–Community (ABC) total score and subscale scores, based on the parent's or primary caretaker's rating, (2) Autism Treatment Evaluation Checklist (ATEC) total score and subscale scores, based on the parent's or primary caretaker's rating, and (3) Clinical Global Impression–Improvement (CGI) scale for changes in overall functioning and subscales, as rated by the parent or primary caretaker and also as rated separately by the treating physician (without knowledge of the parental ratings)	social interaction	0
190	288	365	the number of hospital days after surgery	adjusted average gain in benefit	0
360	1436	650	gastric emptying T half	eiconsenoic acid	0
121	179	454	the proportion of pregnant women who attended ANC with their partners at the subsequent antenatal visit	male partners attended the antenatal clinic	0
502	782	946	the mean time to onset of the first 24-h heartburn-free period after initial dosing	The mean time to onset of the first 24-h heartburn-free period	1
514	796	616	the proportion of children achieving a well clinical response and time to a well clinical response	a 'Well' clinical response	0
753	1936	55	changes compared to baseline observed after 4 weeks (40 sessions) of treatment, in parallel groups, on (1) Aberrant Behavior Checklist–Community (ABC) total score and subscale scores, based on the parent's or primary caretaker's rating, (2) Autism Treatment Evaluation Checklist (ATEC) total score and subscale scores, based on the parent's or primary caretaker's rating, and (3) Clinical Global Impression–Improvement (CGI) scale for changes in overall functioning and subscales, as rated by the parent or primary caretaker and also as rated separately by the treating physician (without knowledge of the parental ratings)	overall functioning	0
265	461	326	10-year CVD risk	estimated population CVD risk	1
45	1072	339	the recruitment rate	This number of centres	0
403	646	209	PCS	Women's physical health scores	0
581	1668	768	the Freezing of Gait Questionnaire	freezing	1
140	207	525	educational achievement and anaemia	The estimated financial cost of IST per child screened	0
695	1834	797	The MC exam	learning joint anatomy	0
182	1250	293	The frequency of acute exacerbation	FEV1	0
354	1434	570	HbA 1c	Hyperglycaemic and hypoglycaemic distress	0
0	1001	381	the average efficacy over Seasons 1 and 2 for the prevention of culture-confirmed influenza illness due to influenza A or B virus strains antigenically matching those in the vaccine (ie vaccine-matched, culture-confirmed influenza; VMCCI)	the point estimate for the primary endpoint, efficacy of TIV against VMCCI across both influenza seasons,	1
166	237	611	Aberrant Behaviour Checklist-Community (ABC-C)	The ABC-C Irritability Subscale scores	0
141	1198	917	utilization rates	number of outpatient visits per patient	0
512	1583	982	an overall response that integrated clinical, bacteriological and radiological results, at the end of treatment (month 6) and after 12 additional months of follow-up (month 18)	bacteriology	0
152	223	830	change in weight from randomization (0-M) to 12 months post randomization	weight regain	1
212	378	277	the duration of the weaning process	PSV levels	0
185	1270	550	90-day mortality	nursing time spent for renal replacement therapy	0
237	1965	199	to test the effect of TA on the incidence of IR and VS in patients undergoing elective CPB	plasminogen activator inhibitor 1	0
126	1153	961	LV mass	LV mass-I	1
495	1567	552	retention on treatment at 1 year	Retention rates	1
276	1337	65	crossover rate	survival without supplemental oxygen or on ventilator	0
436	682	587	trial feasibility, defined by randomization of >25% of eligible patients, delivery of >75% of the prescribed CRRT dose, and follow-up of >95% of patients to 60 days	Baseline SOFA scores	0
523	1596	149	second-progression-free survival	Median overall survival	0
605	1717	365	school rule infractions	rule infractions	1
6	0	1012	the horizontal VAS according to Jensen	VAS	1
452	707	1068	health-related quality of life (HRQoL)	Groningen Activity and Restriction scale	0
575	881	372	the overall discomfort reported during WC versus SC pH-metry	the cost	0
272	1457	355	the proportion of patients who reported being sexually active at six months compared to randomization	sexual activity	1
141	1198	917	utilization rates	utilization (89.7% of patients) with COPD visits	1
217	1276	832	the number of clinical episodes of P. falciparum malaria	fever episodes	0
289	1342	740	"the percentage change in ""average pain for the past 24 hours"" NPRS scores from baseline to weeks 2 through 8"	well tolerated	0
505	782	949	the mean time to onset of the first 24-h heartburn-free period after initial dosing	pain intensity	0
141	1198	917	health care costs	outpatient costs	1
102	158	808	the mean number of detected polyps	the mean number of polyps	1
367	600	33	patient-perceived recovery (PPR) 10	patient-perceived recovery	1
698	1924	794	the anatomical knowledge (MCQ)	The final examination (OSCE)	0
314	1372	821	major adverse cardiac events (MACE) defined as a composite endpoint of cardiac death, myocardial infarction, and target vessel revascularization (TVR)	in-stent restenosis	0
720	1867	605	spontaneous preterm delivery between 34 and 37 weeks' gestation	spontaneous premature birth at < 34 and < 37 weeks' gestation	1
562	861	935	changes in lifestyle according to established goals	Unhealthy diets according to SDS	0
213	378	279	the duration of the weaning process	The duration of the automatic reduction of pressure support	0
712	1846	614	physical activity	body mass index	0
158	224	1067	'first-step' pain (measured on a 100 mm Visual Analogue Scale)	'first-step' pain	1
713	1862	922	pain severity	Verbal Rating Scale for pain (VRS)	1
378	1450	577	mean body temperature after 24 hours of treatment	body temperature	1
719	1862	928	pain severity	levels of pain	1
113	166	349	the percentage of patients who reached 25(OH)D levels of 30 ng/ml or above on day 7	response	0
607	928	389	child body mass index (BMI) z-score	fidelity	0
595	1707	535	CR	vomiting	0
122	179	455	the proportion of pregnant women who attended ANC with their partners at the subsequent antenatal visit	couple antenatal attendance	1
534	814	649	to decrease reintubation rates, defined by the necessity of mechanical positive-pressure ventilation through orotracheal intubation in the first 48 hours after extubation, in the treatment group	the reintubation rates related to NIV failure	1
416	1489	1064	PCR-corrected adequate clinical and parasitological response (ACPR) on day 28	packed cell volume	0
26	1039	155	intestinal volume	effective	0
661	1787	250	the percentage of time the temperature was out of range during the first 24 hours of treatment (defined as more than 0.2°C above or below target temperature)	out of range	1
504	1573	888	the clinical and virological effects of zidovudine in combination with lamivudine	pain	0
143	1198	920	health care costs and utilization rates	treatment costs	0
241	406	265	a dichotomous measure (occurrence of low back pain)	education	0
375	624	261	the percentage of responders according to American College of Rheumatology 50 criteria	Functional Assessment of Chronic Illness Therapy-Fatigue	0
371	607	577	HRQL	physical HRQL	1
206	360	87	the prevalence of arm, shoulder and neck symptoms	symptoms	1
68	1085	863	the levels of inflammatory cells (neutrophils, eosinophils, macrophages, and lymphocytes)	sputum eosinophils	0
300	507	872	the change from baseline to 52 weeks of carotid arterial wall volume, reflecting plaque burden, as measured by carotid cardiovascular magnetic resonance	the carotid arterial wall volume	1
287	1342	738	"the percentage change in ""average pain for the past 24 hours"" NPRS scores from baseline to weeks 2 through 8"	average pain for the past 24 hours NPRS scores	1
308	513	196	Early Treatment Failure (ETF); Late Clinical Failure (LCF); Late Parasitological Failure (LPF); Adequate Clinical and Parasitological Response (ACPR) 18	the cure rate	0
390	632	215	WOMAC Pain	Physical Function	0
605	1717	365	changes in absenteeism, school rule infractions and suspension days during the four-month pretest period prior to randomization compared with the four-month intervention period	absenteeism	0
668	1942	758	patient satisfaction	Functional outcome of the ankle joint	0
581	886	73	Major bleeding	risk of TEs	0
462	712	382	change in urinary HRQOL at 3 months	contralateral local failures	0
117	170	133	duration	severity	0
639	965	25	lung function	Forced Expiratory Volume in 1 second	0
433	1494	47	Number of headache days over a 12 week period (item A MIDAS questionnaire)	the disability	0
16	420	1039	detection of bilateral aerated middle ears (confirmed with tympanometry) at two consecutive monthly visits	the proportion of children with i) perforation at the end of therapy (27% to 12% RD = -16% [-31,-1]), ii) recurrent perforation during therapy (18% to 4% RD = -14% [-25,-2])	0
158	224	1067	'first-step' pain (measured on a 100 mm Visual Analogue Scale) and the Foot Health Status Questionnaire domains of foot pain, foot function and general foot health	general foot health	0
490	1952	16	Kinetic force platform gait analysis (PVF BW )	the CSOM	0
184	1270	549	90-day mortality	days of mechanical ventilation	0
397	1479	601	safety climate, measured using the Safety Climate Survey	responded more favorably to a majority of items on the survey	0
492	770	537	the time until shock reversal	CoQ10 levels	0
238	1965	200	to test the effect of TA on the incidence of IR and VS in patients undergoing elective CPB	VS	0
354	586	14	the American College of Rheumatology 20% improvement criteria (ACR20) response at week 24 19 20	productivity within and outside the home	0
424	1493	208	response rate	data quality	0
608	928	390	child body mass index (BMI) z-score	discouraged healthful eating and PA	0
191	1271	83	change in nutrition knowledge scores	nutrition knowledge	1
9	1016	104	blood pressure	Adherence to pedometer diary self-monitoring	0
314	1372	821	cardiac death	myocardial infarction	0
